Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
Status:
NOT_YET_RECRUITING
Trial end date:
2028-01-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate whether reduction in topical medication with the injection of a sustained release capsule (Durysta) leads to a reduction in ocular surface inflammation, indicated by levels of caspase-1, an inflammatory biomarker.